ESG

Vitaquest's new CEO, Tim Condron, brings deep regulatory and operational expertise, signaling a strategic shift in a rapidly evolving supplement market.

Fintech firm Pagaya's latest AAA-rated deal attracts new investors, signaling strong confidence in its AI-driven lending model despite economic headwinds.

Decoy Therapeutics touts a revolutionary AI platform for multi-virus drugs, but faces financial hurdles. An upcoming investor event could define its future.

A major Canadian carrier is deploying Orange EV electric trucks, signaling a pivotal shift towards sustainable and cost-effective logistics, even in harsh climates.

Vyome is set to present promising Phase 2 data for VT-1953, a first-in-class treatment for a debilitating cancer complication with no approved drugs.

In a pivotal move from R&D to commercial scale, Zivo Bioscience partners with industry leader Cyanotech to meet global demand for its unique algal biomass.

Boston's Bio-IT World conference shifts from AI theory to execution, showcasing how the life sciences industry is now deploying AI to accelerate new therapies.

This April, families nationwide are walking to fund a new strategy for Lennox-Gastaut Syndrome, aiming to slash diagnosis times and find real cures.

Amid financial headwinds, radiation therapy firm Accuray appoints a proven sales leader to spearhead a critical commercial transformation.

Hundreds of thousands of U.S.-born children live in exile after parental deportation. A new initiative aims to restore their rights and build a path home.

With record revenue and A-list fans, British MedTech firm LYMA is doubling down on the US market, blending clinical data with celebrity appeal.

The ASEAN+3 region projects 4.0% growth but faces a severe energy shock. A new report reveals how a structural shift toward internal demand may be its shield.

A new service brings quiet, eco-friendly robotic lawnmowers to Toronto and Hamilton, promising to save homeowners time, money, and weekend headaches.

FDA clears Allevion's Vantage™, a disposable kit with integrated visualization that targets bone growth, aiming to transform spinal decompression.

The final phase of the Tour & Taxis transformation begins, promising a sustainable district with 700+ homes, affordable housing, and geothermal energy.

President Trump's 100% tariff on imported drugs aims to secure the US supply chain, but the policy's success may hinge on unproven and unverified players.

Biopharma firm GENFIT sees soaring Iqirvo sales and a cash runway past 2028, overshadowing a net loss driven by strategic, non-cash write-downs.

MFS postpones a key shareholder vote on a major municipal fund merger, offering a tender to sway investors as Aberdeen prepares to take the helm.

A new partnership aims to tackle the US energy crisis by delivering mobile natural gas to power-hungry data centers and industries the grid can't support.

Manufacturers are spending millions on ERP systems with poor results. Discover why a 'process-first' approach is becoming critical for survival and growth.